broker report says sell with valuation 1.50

Nexavar is quoted as dominating the liver cancer market, leaving just the small niche of liver resection to PI-88. I guess the people in the know could see this happening (and have already exited the stock). So we seem due for a major correction.

I may look to pick some up around $1.50, as this seems close to book value. But I am worried that Nexavar will move into PI-88's market. That could mean we drop even further.

They always say that risky biotechs are only for money you can afford to lose. It's a good principle to guide your investment strategy.